With over 30 years’ experience in pharmaceuticals, Taunia Markvicka serves as the chief commercial officer of Symbiomix Therapeutics in Newark, New Jersey. Taunia Markvicka has taken the lead in launching the company’s new product, Solosec.
Solosec has been approved for treatment of bacterial vaginosis (BV), a condition that affects some 21 million women ages 14-49. It is the most common gynecologic infection in that age group, and strikes women of color disproportionately.
The disease impairs the natural balance of lactobacilli (“good” bacteria) and anaerobic (“bad” bacteria) in the vagina, by producing too many of the anaerobic variety. Symptoms include a thin (gray, white, or green) discharge, a foul, fishy odor, itching, and burning while urinating.
BV has significant health consequences, such as an increased risk of sexually transmitted diseases (trichomoniasis, herpes, chlamydia, and gonorrhea), and untreated BV can lead to infertility. BV also increases the risk of premature birth. It can also lead to complications after gynecologic surgery. This diversity of risks, warrants greater education and research to improve health outcomes.
Risk factors for BV include multiple or new sex partners, same-sex relations among women, douching, and the absence of lactobacilli (“good”) bacteria.